Pieris reports preclinical development progress of its next generation VEGF antagonist

PRS-050 program on track to commence clinical trials as planned

13-Oct-2009 - Germany

Pieris AG reported continued progress in development of its lead therapeutic program for the clinic.

Under its manufacturing agreement with Wacker Biotech GmbH Pieris has successfully completed the first cGMP run of its Anticalin candidate PRS-050, a potent VEGF antagonist with broad therapeutic applicability.

Having established production process parameters for PRS-050 earlier in 2009, Pieris has now met all regulatory CMC requirements to file an IND application by the end of January 2010. With toxicology studies running concurrently, PRS-050 is scheduled to commence first in man studies in the first half of 2010. Progress in the PRS-050 program demonstrates that Anticalin discovery programs can be successfully advanced from lead candidate to GMP production in around twelve months.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance